Biologics,
Journal Year:
2022,
Volume and Issue:
2(3), P. 211 - 212
Published: Aug. 31, 2022
In
this
issue
of
Biologics,
we
publish
an
article
describing
a
surprising
clinical
effect
the
anti-helminthic
drug
ivermectin
on
patients
with
COVID-19
[...]
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(24), P. 15480 - 15480
Published: Dec. 7, 2022
Experimental
findings
for
SARS-CoV-2
related
to
the
glycan
biochemistry
of
coronaviruses
indicate
that
attachments
from
spike
protein
glycoconjugates
on
surfaces
red
blood
cells
(RBCs),
other
and
endothelial
are
key
infectivity
morbidity
COVID-19.
To
provide
further
insight
into
these
their
potential
clinical
relevance,
classic
hemagglutination
(HA)
assay
was
applied
using
Wuhan,
Alpha,
Delta
Omicron
B.1.1.529
lineages
mixed
with
human
RBCs.
The
electrostatic
central
region
four
studied
through
molecular
modeling
simulations.
Inhibition
protein-induced
HA
tested
macrocyclic
lactone
ivermectin
(IVM),
which
is
indicated
bind
strongly
sites.
results
experiments
were,
first,
induced
HA.
at
a
significantly
lower
threshold
concentration
than
three
prior
much
more
electropositive
its
region.
IVM
blocked
when
added
RBCs
reversed
afterward.
These
validate
extend
role
bindings
viral
in
They
furthermore
suggest
therapeutic
options
competitive
glycan-binding
agents
such
as
may
help
elucidate
rare
serious
adverse
effects
(AEs)
associated
COVID-19
mRNA
vaccines,
use
generated
antigen.
Molecular Aspects of Medicine,
Journal Year:
2022,
Volume and Issue:
91, P. 101151 - 101151
Published: Oct. 28, 2022
With
more
than
5
million
fatalities
and
close
to
300
reported
cases,
COVID-19
is
the
first
documented
pandemic
due
a
coronavirus
that
continues
be
major
health
challenge.
Despite
being
rapid,
uncontrollable,
highly
infectious
in
its
spread,
it
also
created
incentives
for
technology
development
redefined
public
needs
research
agendas
fast-track
innovations
translated.
Breakthroughs
computational
biology
peaked
during
with
renewed
attention
making
all
cutting-edge
deliver
agents
combat
disease.
The
demand
develop
effective
treatments
yielded
surprising
collaborations
from
previously
segregated
fields
of
science
technology.
long-standing
pharmaceutical
industry's
aversion
repurposing
existing
drugs
lack
exponential
financial
gain
was
overrun
by
crisis
pressures
front-line
researchers
providers.
Effective
vaccine
even
at
an
unprecedented
pace
took
year
commence
trials.
Now
emergence
variants
waning
protections
booster
shots
resulting
breakthrough
infections
continue
strain
care
systems.
As
now,
every
protein
SARS-CoV-2
has
been
structurally
characterized
related
host
pathways
have
extensively
mapped
out.
community
addressed
druggability
multitude
possible
targets.
This
made
virtual
computer-assisted
drug
as
well
new
tools
technologies
such
artificial
intelligence
leads.
Here
this
article,
we
are
discussing
advances
discovery
field
target-based
exploring
implications
known
target-specific
on
therapeutic
management.
current
scenario
calls
personalized
medicine
efforts
stratifying
patient
populations
early
their
need
different
combinations
prognosis-specific
therapeutics.
We
intend
highlight
target
hotspots
potential
agents,
ultimate
goal
using
rational
design
therapeutics
not
only
end
but
uncover
generalizable
platform
use
future
pandemics.
European journal of medical research,
Journal Year:
2023,
Volume and Issue:
28(1)
Published: Aug. 10, 2023
Abstract
Background
The
reactivation
of
herpesviruses
(HHV)
in
COVID-19
patients
is
evident
the
literature.
Several
reports
have
been
published
regarding
these
viruses
(HSV,
VZV,
EBV,
and
CMV)
among
those
who
got
vaccines.
In
this
study,
we
aimed
to
review
current
evidence
assess
whether
HHVs
has
any
association
with
prior
administration
Methods
A
systematic
search
was
conducted
on
25
September
2022
PubMed/MEDLINE,
Web
Science,
EMBASE.
We
included
all
observational
studies,
case
reports,
series
which
reported
human
following
Results
Our
showed
80
articles
that
meet
eligibility
criteria.
Among
evaluated
vaccines,
most
vaccines
were
mRNA
based.
Evidence
from
studies
possible
relation
between
vaccine
VZV
HSV
reactivation.
results
our
proportion
meta-analysis
rate
received
14
persons
per
1000
vaccinations
(95%
CI
2.97–32.80).
Moreover,
for
16
1.06–46.4).
Furthermore,
reports/series
149
cases
HHV
There
several
caused
including
BNT162b2
or
Pfizer–BioNTech
(
n
=
76),
Oxford-AstraZeneca
22),
mRNA-1273
Moderna
17),
Sinovac
4),
BBIBP-CorV
Sinopharm
3),
Covaxin
Covishield
Johnson
1).
Reactivated
varicella-zoster
virus
(VZV)
114),
cytomegalovirus
(CMV)
15),
herpes
simplex
(HSV)
14),
Epstein-Barr
(EBV)
6),
HHV-6
2).
Most
their
disease
after
first
dose
vaccine.
Many
having
comorbidities,
hypertension,
diabetes
mellitus,
dyslipidemia,
chicken
pox,
atrial
fibrillation
common.
Conclusion
conclusion,
study
vaccination
herpesvirus
supported
by
studies.
However,
other
(EBV
CMV),
further
research
especially
clinical
trials
required
elucidate
interaction
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(23), P. 17039 - 17039
Published: Dec. 1, 2023
Consistent
with
well-established
biochemical
properties
of
coronaviruses,
sialylated
glycan
attachments
between
SARS-CoV-2
spike
protein
(SP)
and
host
cells
are
key
to
the
virus’s
pathology.
SP
attaches
aggregates
red
blood
(RBCs),
as
shown
in
many
pre-clinical
clinical
studies,
causing
pulmonary
extrapulmonary
microthrombi
hypoxia
severe
COVID-19
patients.
heavily
surfaces
platelets
(which,
like
RBCs,
have
no
ACE2)
endothelial
(having
minimal
compound
this
vascular
damage.
Notably,
experimentally
induced
RBC
aggregation
vivo
causes
same
morbidities
for
COVID-19,
including
microvascular
occlusion,
clots,
myocarditis.
Key
risk
factors
morbidity,
older
age,
diabetes
obesity,
all
characterized
by
markedly
increased
propensity
clumping.
For
mammalian
species,
degree
susceptibility
correlates
aggregability
p
=
0.033.
five
human
betacoronaviruses,
two
common
cold
strains
express
an
enzyme
that
releases
attachments,
while
deadly
SARS,
MERS
do
not,
although
viral
loads
infections
similar.
These
insights
also
explain
previously
puzzling
efficacy
certain
generics
against
may
support
development
future
therapeutic
strategies
long
COVID
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Nov. 28, 2022
ABSTRACT
Experimental
findings
for
SARS-CoV-2
related
to
the
glycan
biochemistry
of
coronaviruses
indicate
that
attachments
from
spike
protein
glycoconjugates
on
surfaces
red
blood
cells
(RBCs),
other
and
endothelial
are
key
infectivity
morbidity
COVID-19.
To
provide
further
insight
into
these
their
potential
clinical
relevance,
classic
hemagglutination
(HA)
assay
was
applied
using
Wuhan,
Alpha,
Delta
Omicron
B.1.1.529
lineages
mixed
with
human
RBCs.
The
electrostatic
central
region
four
studied
through
molecular
modeling
simulations.
Inhibition
protein-induced
HA
tested
macrocyclic
lactone
ivermectin
(IVM),
which
is
indicated
bind
strongly
sites.
results
experiments
were,
first,
induced
HA.
at
a
significantly
lower
threshold
concentration
than
three
prior
much
more
electropositive
its
region.
IVM
blocked
when
added
RBCs
reversed
afterwards.
These
validate
extend
role
bindings
viral
in
They
furthermore
suggest
therapeutic
options
competitive
glycan-binding
agents
such
as
may
help
elucidate
rare
serious
adverse
effects
(AEs)
associated
COVID-19
mRNA
vaccines
use
generated
antigen.
Immunity Inflammation and Disease,
Journal Year:
2024,
Volume and Issue:
12(1)
Published: Jan. 1, 2024
The
current
study
aims
to
evaluate
the
impact
of
COVID-19
infection
and
vaccination
on
ovarian
reserve
by
detecting
anti-Mullerian
hormone
(AMH)
level.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(9), P. 7865 - 7865
Published: April 26, 2023
The
coronavirus
disease
2019
(COVID-19)
pandemic,
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
has
become
a
global
health
concern.
Three
years
since
its
origin,
despite
the
approval
of
vaccines
and
specific
treatments
against
this
new
coronavirus,
there
are
still
high
rates
infection,
hospitalization,
mortality
in
some
countries.
COVID-19
is
characterised
inflammatory
state
coagulation
disturbances
that
may
be
linked
to
purinergic
signalling
molecules
such
as
adenosine
triphosphate
(ATP),
diphosphate
(ADP),
(ADO),
receptors
(P1
P2).
These
nucleotides/nucleosides
play
important
roles
cellular
processes,
immunomodulation,
blood
clot
formation,
vasodilation,
which
affected
during
SARS-CoV-2
infection.
Therefore,
drugs
targeting
pathway,
currently
used
for
other
pathologies,
being
evaluated
preclinical
clinical
trials
COVID-19.
In
review,
we
focus
on
potential
these
control
release,
degradation,
reuptake
extracellular
nucleotides
nucleosides
treat
Drugs
P1
could
have
therapeutic
efficacy
due
their
capacity
modulate
cytokine
storm
immune
response.
Those
acting
P2X7,
NLRP3
inflammasome
activation,
also
valuable
candidates
they
can
reduce
release
pro-inflammatory
cytokines.
However,
according
available
data,
most
promising
medications
treatment
those
platelets
behaviour
factors,
mainly
through
P2Y12
receptor.